Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

1.280 +0.060 (+4.93%)
Streaming Delayed Price Updated: 10:07 AM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,826
Open 1.200
Bid (Size) 1.180 (19)
Ask (Size) 1.290 (1)
Prev. Close 1.220
Today's Range 1.200 - 1.280
52wk Range 0.6105 - 7.041
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nottingham University Researchers Find Way to Make Brain Cancer Cells Self-Destruct
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients
Via Investor Brand Network

Performance

YTD
-51.87%
-51.87%
1 Month
-26.43%
-26.43%
3 Month
-46.88%
-46.88%
6 Month
+21.92%
+21.92%
1 Year
-80.29%
-80.29%

More News

Read More
Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments
Via Investor Brand Network
Study Shares Insights on Why Brain Tumors Are Unresponsive to Immunotherapy
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Via ACCESSWIRE
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
Policies Encouraging High-Volume Facilities Disadvantage Oncology Patients in Rural Areas
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
Via Investor Brand Network
AI Helps Forecast Brain Tumor Outcomes
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Canadian Researchers Design Powerful Imaging Tech to Boost Cancer Fight
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Researchers Develop Novel Way to Detect Pediatric Brain-Cancer Mutations
Via Investor Brand Network
How Healthcare eCommerce Impacts Traditional Providers of Healthcare
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Via ACCESSWIRE
Israeli Company Seeks to Develop Micro-Robots to Boost Precision Medicine
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
Via Investor Brand Network
Exposures COVID-19
CNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!
Via Benzinga
Researchers Unlock Previously Unknown Weakness of Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.